Coprimary end points and hematologic parameters over time. (A) Coprimary end points of hemoglobin stabilization (defined as avoidance of >1-g/dL decrease in hemoglobin levels from baseline through week 26) and CFB in LDH levels at week 26 in patients in the pegcetacoplan group or control group. Reference range for normal LDH levels: 113 to 226 U/L. (B) Mean hemoglobin levels (±standard error [SE]) and (C) mean LDH over time (±SE) for patients in the pegcetacoplan group or control group. Reference range for normal hemoglobin levels: male, 13.6 to 18 g/dL; female, 12 to 16 g/dL. SE bars are not visible on data points representing mean values with small SE. ∗ indicates control group patients received supportive care (eg, transfusions, corticosteroids, and supplements [iron, folate, and vitamin B12]) and †, avoidance of >1-g/dL decrease in hemoglobin levels from baseline through week 26. Patients who received a transfusion, escaped from the control arm to pegcetacoplan treatment, withdrew from the study before week 26, or were lost to follow-up were categorized as failing to achieve hemoglobin stabilization. ‡ indicates from baseline to week 26.